117 related articles for article (PubMed ID: 21153923)
1. The investigation of allele and genotype frequencies of CYP3A5 (1/3) and P2Y12 (T744C) in Iran.
Azarpira N; Namazi S; Khalili A; Tabesh M
Mol Biol Rep; 2011 Nov; 38(8):4873-7. PubMed ID: 21153923
[TBL] [Abstract][Full Text] [Related]
2. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
[TBL] [Abstract][Full Text] [Related]
3. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
4. Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population.
Vargas-Alarcón G; Ramírez-Bello J; de la Peña A; Calderón-Cruz B; Peña-Duque MA; Martínez-Ríos MA; Ramírez-Fuentes S; Pérez-Méndez O; Fragoso JM
Mol Biol Rep; 2014 Oct; 41(10):7023-9. PubMed ID: 25106522
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
[TBL] [Abstract][Full Text] [Related]
6. The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Isordia-Salas I; Olalde-Román MJ; Santiago-Germán D; de la Peña NC; Valencia-Sánchez JS
Thromb Res; 2012 Sep; 130(3):e67-72. PubMed ID: 22819265
[TBL] [Abstract][Full Text] [Related]
7. CYP3A5*3 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups.
Lai Y; Zhang J; Wang YX; Wang XD; Li JL; Wang YH; Zeng YJ; Huang M
Pharmazie; 2011 Feb; 66(2):136-40. PubMed ID: 21434577
[TBL] [Abstract][Full Text] [Related]
8. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel.
Mirzaev KB; Samsonova KI; Potapov PP; Andreev DA; Grishina EA; Ryzhikova KA; Sychev DA
Mol Biol Rep; 2019 Aug; 46(4):4195-4199. PubMed ID: 31102151
[TBL] [Abstract][Full Text] [Related]
9. The investigation of allele and genotype frequencies of human C3 (rs2230199) in south Iranian population.
Bazyar N; Azarpira N; Khatami SR; Galehdari H
Mol Biol Rep; 2012 Sep; 39(9):8919-24. PubMed ID: 22718507
[TBL] [Abstract][Full Text] [Related]
10. Allele and genotype frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 gene polymorphisms among mainland Tibetan, Mongolian, Uyghur, and Han Chinese populations.
Qi G; Han C; Zhou Y; Wang X
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):219-227. PubMed ID: 34689350
[TBL] [Abstract][Full Text] [Related]
11. Significant interethnic differencies in functional variants of PON1 and P2RY12 genes in Roma and Hungarian population samples.
Janicsek I; Sipeky C; Bene J; Duga B; Melegh BI; Sümegi K; Jaromi L; Magyari L; Melegh B
Mol Biol Rep; 2015 Jan; 42(1):227-32. PubMed ID: 25297118
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
[TBL] [Abstract][Full Text] [Related]
14. Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.
Sun B; Li J; Dong M; Yang L; Wu C; Zhu L; Cong YL
Genet Mol Res; 2015 Feb; 14(1):1434-42. PubMed ID: 25730082
[TBL] [Abstract][Full Text] [Related]
15. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 3A5 in a Uyghur Chinese population.
Chen Z; Li J; Chen P; Wang F; Zhang N; Yang M; Jin T; Chen C
Xenobiotica; 2016 Sep; 46(9):850-6. PubMed ID: 26739429
[TBL] [Abstract][Full Text] [Related]
17. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.
Hiratsuka M; Takekuma Y; Endo N; Narahara K; Hamdy SI; Kishikawa Y; Matsuura M; Agatsuma Y; Inoue T; Mizugaki M
Eur J Clin Pharmacol; 2002 Sep; 58(6):417-21. PubMed ID: 12242601
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 variant allele frequencies in Dutch Caucasians.
van Schaik RH; van der Heiden IP; van den Anker JN; Lindemans J
Clin Chem; 2002 Oct; 48(10):1668-71. PubMed ID: 12324482
[TBL] [Abstract][Full Text] [Related]
19. CYP2E1*5B, CYP2E1*6, CYP2E1*7B, CYP2E1*2, and CYP2E1*3 allele frequencies in iranian populations.
Shahriary GM; Galehdari H; Jalali A; Zanganeh F; Alavi SM; Aghanoori MR
Asian Pac J Cancer Prev; 2012; 13(12):6505-10. PubMed ID: 23464483
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
